Grodin Erica N
Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USA.
Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA.
Brain Behav Immun Health. 2024 Feb 22;36:100744. doi: 10.1016/j.bbih.2024.100744. eCollection 2024 Mar.
One promising avenue of research is the use of neuroimmune modulators to treat substance use disorders (SUDs). Neuroimmune modulators target the interactions between the nervous system and immune system, which have been found to play a crucial role in the development and maintenance of SUDs. Multiple classes of substances produce alterations to neuroimmune signaling and peripheral immune function, including alcohol, opioids, and psychostimulants Preclinical studies have shown that neuroimmune modulators can reduce drug-seeking behavior and prevent relapse in animal models of SUDs. Additionally, early-phase clinical trials have demonstrated the safety and feasibility of using neuroimmune modulators as a treatment for SUDs in humans. These therapeutics can be used as stand-alone treatments or as adjunctive. This review summarizes the current state of the field and provides future directions with a specific focus on personalized medicine.
一个有前景的研究方向是使用神经免疫调节剂来治疗物质使用障碍(SUDs)。神经免疫调节剂针对神经系统和免疫系统之间的相互作用,已发现这种相互作用在SUDs的发生和维持中起关键作用。多种物质会导致神经免疫信号和外周免疫功能的改变,包括酒精、阿片类药物和精神兴奋剂。临床前研究表明,神经免疫调节剂可以减少动物模型中SUDs的觅药行为并预防复发。此外,早期临床试验已经证明了使用神经免疫调节剂治疗人类SUDs的安全性和可行性。这些疗法可以单独使用或作为辅助治疗。本综述总结了该领域的现状,并提供了未来的方向,特别关注个性化医疗。